Remebering Malaria in COVID-19

Hlumelo Matshanda • April 29, 2020
Historically, malaria is still considered one of the world’s deadliest diseases. In the midst of a global pandemic, efforts by healthcare sectors to curb the spread of malaria now has to face off with COVID-19 in a desperate struggle for adequate resources and public attention.

Although both diseases share the characteristics of not respecting borders and if not treated timeously may lead to devastating effects, they are fundamentally different. It is vital that the public understands the risks of COVID-19 and Malaria in a world where one can contract the two at the same time and both pose a significant health threat.

On the one hand, COVID-19 has caused most of the world to go into lockdown with devastating economic impact. This completely new (novel) virus has no known cure, leaving scientists scrambling to develop a vaccine. COVID-19 symptoms include a fever, cough and shortness of breath.

On the other hand, Malaria infects more than 230 million people every year with a death toll of over 400,000. Spread by the anopheles mosquito, 90% of malaria cases occur in malaria-prone areas like Sub-Saharan Africa. Symptoms of malaria include fever, headache, nausea and the chills.

Having said that, malaria is easily diagnosed with a simple prick of the finger. If not treated within 24 hours of the onset of symptoms, it can progress to severe illness and in some cases, if not treated, death shortly thereafter especially among children under the age of 5.

When looking at the symptoms, some similarity between the two can be found. Both diseases are identified by high-grade fevers, headaches, shivers and fatigue. According to Sherwin Charles, co-founder and CEO of Goodbye Malaria, “The difference is, a sore throat, cough and shortness of breath are not common features of malaria and would more likely indicate a COVID-19 infection.” If you show any of the shared symptoms and live in a malaria area, Charles urges that the best thing you can do is to first have the malaria test done. Diagnosis and treatment can be obtained from any local clinic. Health professional should be actively aware of the potential COVID-19 infection and should know that malaria can prove fatal in the short term but should employ COVID-19 safety precautions.

According to Prof Lucille Blumberg, Deputy Director of the National Institute for Communicable Diseases (NICD), “Unlike COVID-19, malaria is common, seasonal and treatable and any delay in diagnosis may lead to complications and death. Ignoring killer diseases like malaria in the fight against COVID-19 could amplify devastation by undermining the provision of health services for other diseases.” Prof Blumberg from the NICD says time is of the essence if you do have malaria. “You will need urgent treatment. Once you test negative for malaria, you can investigate further by having a COVID-19 test done.”

As the co-founder of Goodbye Malaria, an organisation deeply entrenched in the fight against malaria, Charles says mosquitoes that carry the malaria-causing parasite usually strike between dusk and dawn but there are many precautions that can be taken to avoid their deadly bite.

“You can protect yourself by spraying your home, wearing long pants and shirts, making use of fans and mosquito repellent. If you are travelling to a malaria area, you can also take anti-malarial medication which has proven an extremely effective method of prevention,” says Charles.

Most of these prevention methods can be accomplished while locked down at home and generally don’t require anything you don’t already own or can’t easily obtain from the local supermarket or pharmacy. Charles says that the spread of COVID-19 and existing malaria epidemics may be challenging to differentiate in people but health systems must remain cognisant of all threats.

“It is vital that the testing process is done right. In circumstances where it is unknown whether one has malaria or COVID-19, they should test for malaria but keep COVID-19 precautions in mind. We have treatments to prevent and cure malaria. This is a fight we can win, if we build and maintain unwavering commitment. We can’t let the fight against malaria slip as we find ourselves confronted by a new enemy.”  
Cardiologist Dr Robert Routier and cardiothoracic intensive care unit manager Sr Nondumiso Fakude
April 1, 2025
Cardiologist Dr Robert Routier urges the public to check their personal risk factors regularly to help prevent or manage cardiovascular disease.
Obstetrician and gynaecologist Dr Natalie Odell
March 26, 2025
The physical strain pregnancy puts on an expectant mother’s body should not be underestimated. An obstetrician gynaecologist offers her insights for alleviating discomfort and promoting wellbeing with exercise and stretching throughout pregnancy.
Dr Patience Sigwadi
March 19, 2025
Dr Patience Sigwadi, a leading paediatric nephrologist practising at Netcare Unitas Hospital in Centurion, has issued an urgent call for increased focus on skills development to address the escalating kidney disease crisis among children in South Africa.
Paediatric Nephrologist Prof Rajendra Bhimma
March 11, 2025
Paediatric Nephrologist Professor Bhimma was recently awarded the Fellowship to acknowledge his extensive work in research, community-based outreach and teaching of paediatric nephrology, among others.
Prof Bhekifa Dube
March 7, 2025
Netcare congratulates Professor Bhekifa Dube on his invitation to join the European Society for Vascular Surgery's clinical practice guidelines committee. His selection as the only specialist from the continent highlights the significance of this achievement on the global stage.
Rare Disease Day on 28 February 2025
February 28, 2025
The lives of millions of South Africans with a litany of rare diseases can be vastly improved, and even saved, by addressing challenges in identifying, studying and treating their conditions. With Rare Disease Day on the 28th of February 2025, the Rare Diseases Access Initiative (RDAI) is driving an evolution of the country’s healthcare, through innovative strategies to better care for over 4.2million people living with an estimated 7000 rare diseases. “As our healthcare system faces significant changes in the years ahead, it is vital that we also advocate for people living with rare diseases in South Africa, especially those with limited healthcare access,” said Kelly du Plessis, CEO of Rare Diseases South Africa (RDSA), a member of RDAI. “As part of our ongoing research and awareness efforts, RDAI has conducted an initial analysis of the incidence and prevalence of rare diseases within the country.” This research will assist in improving access to healthcare, policy development, and patient advocacy, while giving critical insight into the challenges faced by patients. “According to research, some rare diseases affect fewer than 1 in a million people, while others, such as Down syndrome, cystic fibrosis, and haemophilia, have a more recognisable prevalence,” says Dr. Helen Malherbe, RDAI lead researcher on rare disease prevalence data. “Many conditions are undetected, underdiagnosed or misdiagnosed, with too many having no information available about them at all.” The RDAI was formed in 2019 to promote a more favourable environment for those impacted by rare diseases in South Africa. Participants include Ampath, the Board of Healthcare Funders (BHF), Discovery Health, Genetic Counsellors South Africa (SASHG), the Government Employees Medical Scheme (GEMS), Health Funders Association (HFA), Medihelp, Medscheme, North-West University (NWU), Rare Diseases South Africa (RDSA), the South African Medical Association (SAMA) and The South African Medical Technology Industry Association (SAMED). The Council for Medical Schemes (CMS) participates as an observer. In the same year, Rare Disease International signed a memorandum of understanding with the World Health Organisation leading to an international rare disease policy framework. In 2021, the United Nations General Assembly moved to adopt a resolution recognising 300 million people living with rare diseases worldwide. “A general lack of awareness and delayed diagnosis remain major hurdles for those affected by rare diseases. Policymakers and healthcare stakeholders need to prioritise access to treatment, diagnosis, and support for rare disease patients,” says Bada Pharasi, CEO of IPASA, “Through this initiative, working collaboratively with stakeholders at every level of the healthcare supply chain, we can bring real and meaningful change to those affected, including family members and care givers, through smart and efficient strategies.” The globally agreed definition of a rare disease is any medical condition with a specific pattern of clinical signs, symptoms, and findings that affects fewer than or equal to 1 in 2000 persons in a population. “Most are genetic, and some are inherited and passed down in families,” Malherbe says. “Some affect only the patient’s genetic recipe, while others may be acquired during life due to infection, trauma, or environmental effects. For many, the cause is still unknown. “These conditions mainly affect children, as they are largely incurable and many are life-threatening. Some require specialised and co-ordinated care, some have limited and expensive treatment options, while others have no information or effective treatments at all,” she adds. The RDAI is calling for a patient-centred care model built on equitable access, transparency and efficiency. Naturally, this model calls for the open participation of patients, the healthcare industry, health professionals, and the Government. “The most critical elements are robust diagnosis standards, improved access to treatment, data collection and management, co-ordination of care, measurement of outcomes and ongoing collaborative research,” du Plessis says. “We need to establish rare disease advisory committees, map gaps and opportunities, establish system requirements, create a roadmap and plan a phased implementation with clear timelines.” The RDAI states that these policy development steps would be a start in quantifying the disease burden and defining standards of care. This would be followed by building and strengthening the capacity to facilitate appropriate diagnosis, treatment, continuity and data monitoring. Thoneshan Naidoo, Chief Executive Officer of the Health Funders Association noted that, “We appreciate the unique opportunity provided by RDAI which enables stakeholders across the industry to work together and identify strategies that improve equitable access to the appropriate diagnosis, treatment and healthcare services for rare disease patients, in an affordable and sustainable manner, taking account of the other pressing needs across the healthcare system.” “True innovation in healthcare is only possible through partnerships and joint advocacy efforts that raise awareness and improve access to treatment. Our long-term goal is the development of a rare diseases policy framework and guidelines for coordinated care,” says Pharasi. “Our members are united in the commitment to unlocking improved patient outcomes and improving access to services and robust health needs assessment facilities.” he concludes. About RDAI The Rare Diseases Access Initiative (RDAI) is dedicated to advocating for improved healthcare access, policy development, and patient support for those affected by rare diseases in South Africa. The initiative brings together key healthcare stakeholders, including pharmaceutical associations, funders, genetic specialists, and patient advocacy groups, to drive impactful change. About RDSA Founded in 2013, Rare Diseases South Africa (RDSA) is a non-profit organisation advocating to ensure that people living with rare diseases and congenital disorders experience greater recognition, support, improved health service and better overall quality of life. Started out of personal need following the diagnosis of organisation founder, Kelly du Plessis' son, it became evident that there was a lack of awareness and support for rare diseases in general in South Africa. About IPASA The Innovative Pharmaceutical Association South Africa (IPASA) is a voluntary trade association representing 24 leading pharmaceutical companies committed to research, development, and innovation. Our mission is to drive healthcare advancement by advocating for policies that improve patient access to safe, high-quality, and affordable medicines.
Gastroenterologist Dr Barbara Makumbi explains the toll acid reflux can take on your health
February 26, 2025
Gastroenterologist Dr. Barbara Makumbi discusses common risk factors and offers tips for managing reflux and the longer-term condition known as gastroesophageal reflux disease (GORD).
Netcare St Anne’s Hospital emergency department now has both trauma and emergency  specialists.
February 19, 2025
From treating trauma injuries caused by wildlife, road accidents and sports, to heart attacks, stroke, or the sudden onset of other concerning medical symptoms – the emergency department at Netcare St Anne’s Hospital never sleeps.
Making sense of self-harm
February 10, 2025
As many as one in ten teenagers may self-harm, often in secret, concealing the scars or evidence of their injuries. As Teen Suicide Prevention Week approaches, Netcare Akeso is highlighting the often-hidden struggle of self-harm among young people.
Dr Prinitha Pillay is a radiation and clinical oncologist
February 4, 2025
With one in four South Africans affected by cancer, either directly or through a loved one’s diagnosis, the importance of regular screenings cannot be overstated.
More Posts
Share by: